Our findings collectively suggest that 3-MA exerts therapeutic effects on DE through multiple mechanisms: (1) reducing escape latency in diabetic mice, (2) ameliorating cognitive deficits, and (3) decreasing APP and Tau aggregation in brain tissues. Here, APP is linked to Cognitive impairment.